Answers are grounded in this paper and cite their sources.
Observational study shows OCTN1 L503F variant predicts better response to anti-TNFα in ulcerative colitis, suggesting genetic screening may guide therapy.
Background Ulcerative colitis (UC) is a chronic, invalidating condition with a multifactorial aetiology. Several medications are available1; however, few data exist on predictors of response to such therapies. Genetics plays a pivotal role in disease predisposition and prognosis. OCTN1, an organic cation transporter, has been investigated as a modulator of intestinal inflammation. Genetic polymorphisms of OCTN1 have been linked to an increased susceptibility to IBD, but their role in predicting treatment response remains unclear2,3. In mice with colitis, Octn1-/- is associated with a less severe course of disease and a higher percentage of Treg in comparison to wild-type mice4. AIM: To investigate the association between Octn1 genotypes and clinical response to anti-TNFα treatment in patients with UC. Methods We conducted a retrospective, single-center observational study at Policlinico “A. Gemelli” IRCCS, Rome. We enrolled adult patients diagnosed with UC and candidates to start treatment with anti-TNFα agents (infliximab, adalimumab, or golimumab). Individuals with known antibodies against infliximab or adalimumab and patients with a documented allergic reaction to these medications were excluded. Clinical and endoscopic data were collected at baseline and at 12 months of therapy. Patients were genotyped for the Octn1 SNP 1050152 (c1672t), and classified as wild-type (503L), heterozygous, or homozygous mutant (503F). 1 year therapy persistence, endoscopic response (defined as an improvement in endoscopic Mayo score) sustained clinical improvement in the absence of corticosteroid use (over the previous 12 weeks) were assessed as clinical endpoints. Results Of the 105 patients enrolled, 22 were homozygous for the 503F variant, 49 were heterozygous, and 34 presented two wild-type alleles. No statistically significant differences were observed between the patient groups with regard to gender, age at diagnosis, age and Mayo Endoscopic Score at initiation of therapy, duration of disease, or extent of diagnosis.Octn1 mutated patients (503F) patients displayed greater rates of steroid-free clinical remission (OR = 4.86, 95% CI 1.45 - 16.3; p = 0.010) and endoscopic improvement (OR = 6.52, 95% CI 1.93- 22.0; p = 0.003) after one year of therapy. Both the results were confirmed at the multivariable analysis (OR = 4.82 for steroid free clinical remission and OR = 7.94 for endoscopic response). Statistical significance was found for the mere therapy persistence (OR = 16.58, p = 0.009). Conclusion Homozygosity for the rs1050152 c/t Octn1 polymorphism appears to predict a more favorable clinical response to anti-TNFα therapy in ulcerative colitis, as evidenced by improved endoscopic outcomes and reduced need for corticosteroids after one year. References: 1 Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2-17. doi:10.1093/ecco-jcc/jjab178 2 Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36(5):471-475. doi: https://doi.org/ 10.1038/ng1339 3 Taubert D, Grimberg G, Jung N, Rubbert A, Schömig E.. Functional role of the 503F variant of the organic cation transporter OCTN1in Crohn’s disease. Gut. 2005;54(10):1505-1506. doi: https://doi.org/ 10.1136/gut.2005.076083 4 Del Chierico F, Masi L, Petito V, et al. Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation. Inflamm Bowel Dis. 2024;30(12):2259-2270.doi:10.1093/ibd/izae135 Conflict of interest: Puca, Pierluigi: No conflict of interest Masi, Letizia: None Dr. Parello, Simone: No conflict of interest Poscia, Andrea: No conflict of interest Capobianco, Ivan: No Conflict of interest to declare Napolitano, Daniele: No conflict of interest Coppola, Gaetano: No conflict of interest Del Chierico, Federica: No conflict of interest Putignani, Lorenza: No conflict of interest Fidaleo, Marco: No conflict of interest Lopetuso, Loris Riccardo: No conflict of interest Petito, Valentina: None Papa, Alfredo: No conflict of interest Gasbarrini, Antonio: No conflict of interest Pani, Giovambattista: No conflict of interest Scaldaferri, Franco: No conflict of interest
No takes yet. Share an insight, caveat, or question.
Puca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: